LTC3057969I2 - Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit - Google Patents
Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kitInfo
- Publication number
- LTC3057969I2 LTC3057969I2 LTPA2021003C LTPA2021003C LTC3057969I2 LT C3057969 I2 LTC3057969 I2 LT C3057969I2 LT PA2021003 C LTPA2021003 C LT PA2021003C LT PA2021003 C LTPA2021003 C LT PA2021003C LT C3057969 I2 LTC3057969 I2 LT C3057969I2
- Authority
- LT
- Lithuania
- Prior art keywords
- kit
- treatment
- disorders associated
- compositions used
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Jellies, Jams, And Syrups (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892086P | 2013-10-17 | 2013-10-17 | |
| US201461931204P | 2014-01-24 | 2014-01-24 | |
| US201461975229P | 2014-04-04 | 2014-04-04 | |
| PCT/US2014/060746 WO2015057873A1 (en) | 2013-10-17 | 2014-10-15 | Compositions useful for treating disorders related to kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTPA2021003I1 LTPA2021003I1 (lt) | 2021-04-12 |
| LTC3057969I2 true LTC3057969I2 (lt) | 2022-09-26 |
Family
ID=51904226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14799576.5T LT3057969T (lt) | 2013-10-17 | 2014-10-15 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| LTPA2021003C LTC3057969I2 (lt) | 2013-10-17 | 2021-03-16 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14799576.5T LT3057969T (lt) | 2013-10-17 | 2014-10-15 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US9200002B2 (lt) |
| EP (2) | EP3409674B1 (lt) |
| JP (2) | JP6446040B2 (lt) |
| KR (1) | KR102378689B1 (lt) |
| CN (2) | CN105658652B (lt) |
| AU (1) | AU2014337314B2 (lt) |
| BR (1) | BR112016008541B1 (lt) |
| CA (1) | CA2926999C (lt) |
| CY (2) | CY1121182T1 (lt) |
| DK (1) | DK3057969T3 (lt) |
| ES (2) | ES2923888T3 (lt) |
| HR (1) | HRP20181388T1 (lt) |
| HU (3) | HUE039687T2 (lt) |
| IL (1) | IL244677B (lt) |
| LT (2) | LT3057969T (lt) |
| MX (1) | MX365614B (lt) |
| NL (1) | NL301094I2 (lt) |
| NO (1) | NO2021012I1 (lt) |
| PH (1) | PH12016500611A1 (lt) |
| PL (2) | PL3057969T3 (lt) |
| PT (2) | PT3409674T (lt) |
| RS (1) | RS57542B1 (lt) |
| RU (1) | RU2706235C2 (lt) |
| SG (1) | SG11201602937UA (lt) |
| SI (1) | SI3057969T1 (lt) |
| SM (1) | SMT201800448T1 (lt) |
| TW (1) | TWI683814B (lt) |
| UY (1) | UY35787A (lt) |
| WO (1) | WO2015057873A1 (lt) |
| ZA (1) | ZA201601970B (lt) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| FR3008779B1 (fr) | 2013-07-19 | 2018-01-26 | Areva Np | Barre antivibratoire pour faisceau de tubes d'un generateur de vapeur |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PT3409674T (pt) | 2013-10-17 | 2022-07-18 | Blueprint Medicines Corp | Processo para preparar composições úteis para tratar distúrbios relacionados com kit |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| CA2945674A1 (en) * | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| RU2018106483A (ru) | 2015-07-24 | 2019-08-26 | Блюпринт Медсинс Корпорейшн | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
| FI3442977T3 (fi) * | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US10035789B2 (en) * | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| CN108191874B (zh) * | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| JP7710223B2 (ja) * | 2018-04-16 | 2025-07-18 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 |
| WO2019165566A1 (es) | 2018-06-22 | 2019-09-06 | Comercializadora Innvento S.A. | Artículo filtrante-absorbente multicapa que comprende una primera capa de un soporte poroso de carbón activado dispuesto sobre un fieltro no tejido de fibras de poliéster, una segunda capa de una película de polímero y una tercera capa de un agente activo; proceso para obtener dicho artículo; y uso del mismo |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| TW202039862A (zh) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| CN109232583A (zh) * | 2018-11-29 | 2019-01-18 | 尚科生物医药（上海）有限公司 | 一种6-溴-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮的制备方法 |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| CN111410648B (zh) * | 2019-01-07 | 2024-03-29 | 浙江海正药业股份有限公司 | 一种手性c-KIT抑制剂药物关键中间体及其制备方法 |
| SMT202300447T1 (it) * | 2019-04-12 | 2024-01-10 | Blueprint Medicines Corp | Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione |
| SI3953357T1 (sl) | 2019-04-12 | 2024-08-30 | Blueprint Medicines Corporation | Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA |
| AU2020278162A1 (en) | 2019-05-21 | 2021-11-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a BTK inhibitor |
| US20220267334A1 (en) * | 2019-07-09 | 2022-08-25 | Sandoz Ag | Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor |
| JP2022551105A (ja) | 2019-10-04 | 2022-12-07 | ブループリント メディシンズ コーポレイション | アバプリチニブでの好酸球性障害の治療 |
| GB201915447D0 (en) | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| US20220370465A1 (en) * | 2019-11-04 | 2022-11-24 | Blueprint Medicines Corporation | Treatment of mast cell diseases and eosinophilic disorders |
| WO2021113492A1 (en) | 2019-12-06 | 2021-06-10 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| CN110950872A (zh) * | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) * | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| EP4118084A1 (en) | 2020-03-11 | 2023-01-18 | Teva Czech Industries s.r.o. | Solid state forms of avapritinib and process for preparation thereof |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| EP4168119A1 (en) * | 2020-06-17 | 2023-04-26 | Teva Czech Industries s.r.o. | Solid state forms of avapritinib salts |
| TW202212354A (zh) | 2020-08-03 | 2022-04-01 | 美商健生生物科技公司 | 用於病毒治療劑中之多向生物運輸的材料及方法 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| WO2022081626A1 (en) | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| WO2022081627A1 (en) | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| CN112552339A (zh) * | 2020-12-10 | 2021-03-26 | 安徽昊帆生物有限公司 | 一种o-二苯基磷酰羟胺的制备方法 |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| CN113686987B (zh) * | 2021-08-19 | 2022-04-26 | 海南医学院 | 一种用于检测Avapritinib中间体中对映异构体的方法 |
| WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| EP4511366A1 (en) | 2022-04-19 | 2025-02-26 | Blueprint Medicines Corporation | Kit inhibitors |
| US20240382493A1 (en) * | 2023-05-18 | 2024-11-21 | Blueprint Medicines Corporation | Methods for treating systemic mastocytosis and gastrointestinal stromal tumors |
| CN121194786A (zh) * | 2023-06-02 | 2025-12-23 | Idrx股份有限公司 | 用于治疗癌症的包含kit抑制剂的组合疗法 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2025170989A1 (en) | 2024-02-05 | 2025-08-14 | Blueprint Medicines Corporation | High-risk disease features of indolent systemic mastocytosis and methods for treating |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| ES2258459T3 (es) * | 1999-05-21 | 2006-09-01 | Bristol-Myers Squibb Company | Pirrolotriazinas inhibidoras de quinasas. |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| US6784603B2 (en) * | 2001-07-20 | 2004-08-31 | Teledyne Lighting And Display Products, Inc. | Fluorescent lighting apparatus |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| BR0309669A (pt) | 2002-04-23 | 2005-03-01 | Bristol Myers Squibb Co | Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| KR101312736B1 (ko) * | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| WO2005115397A2 (en) | 2004-04-29 | 2005-12-08 | Pharmix Corporation | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JP5116687B2 (ja) * | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5256047B2 (ja) * | 2006-01-27 | 2013-08-07 | シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド | ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤 |
| CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
| WO2008005956A2 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| WO2009117157A1 (en) | 2008-03-20 | 2009-09-24 | Amgen Inc. | Aurora kinase modulators and method of use |
| KR20100003912A (ko) | 2008-07-02 | 2010-01-12 | 삼성전자주식회사 | 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| US20130023497A1 (en) | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| CA2789711C (en) | 2010-02-17 | 2014-08-05 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| WO2012085745A1 (en) * | 2010-12-23 | 2012-06-28 | Pfizer Inc. | Glucagon receptor modulators |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR102212923B1 (ko) | 2012-12-21 | 2021-02-04 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| PT3409674T (pt) | 2013-10-17 | 2022-07-18 | Blueprint Medicines Corp | Processo para preparar composições úteis para tratar distúrbios relacionados com kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| RU2018106483A (ru) | 2015-07-24 | 2019-08-26 | Блюпринт Медсинс Корпорейшн | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| TW202039862A (zh) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| SMT202300447T1 (it) | 2019-04-12 | 2024-01-10 | Blueprint Medicines Corp | Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
-
2014
- 2014-10-15 PT PT181702648T patent/PT3409674T/pt unknown
- 2014-10-15 CN CN201480056950.4A patent/CN105658652B/zh active Active
- 2014-10-15 CN CN201910192873.XA patent/CN110003217B/zh active Active
- 2014-10-15 ES ES18170264T patent/ES2923888T3/es active Active
- 2014-10-15 WO PCT/US2014/060746 patent/WO2015057873A1/en not_active Ceased
- 2014-10-15 SG SG11201602937UA patent/SG11201602937UA/en unknown
- 2014-10-15 PT PT147995765T patent/PT3057969T/pt unknown
- 2014-10-15 HU HUE14799576A patent/HUE039687T2/hu unknown
- 2014-10-15 MX MX2016004927A patent/MX365614B/es active IP Right Grant
- 2014-10-15 ES ES14799576.5T patent/ES2683127T3/es active Active
- 2014-10-15 DK DK14799576.5T patent/DK3057969T3/en active
- 2014-10-15 EP EP18170264.8A patent/EP3409674B1/en active Active
- 2014-10-15 RS RS20180915A patent/RS57542B1/sr unknown
- 2014-10-15 EP EP14799576.5A patent/EP3057969B1/en active Active
- 2014-10-15 AU AU2014337314A patent/AU2014337314B2/en active Active
- 2014-10-15 HU HUE18170264A patent/HUE059041T2/hu unknown
- 2014-10-15 RU RU2016118768A patent/RU2706235C2/ru active
- 2014-10-15 BR BR112016008541-8A patent/BR112016008541B1/pt active IP Right Grant
- 2014-10-15 KR KR1020167012391A patent/KR102378689B1/ko active Active
- 2014-10-15 CA CA2926999A patent/CA2926999C/en active Active
- 2014-10-15 JP JP2016523939A patent/JP6446040B2/ja active Active
- 2014-10-15 PL PL14799576T patent/PL3057969T3/pl unknown
- 2014-10-15 PL PL18170264.8T patent/PL3409674T3/pl unknown
- 2014-10-15 LT LTEP14799576.5T patent/LT3057969T/lt unknown
- 2014-10-15 HR HRP20181388TT patent/HRP20181388T1/hr unknown
- 2014-10-15 US US14/515,327 patent/US9200002B2/en active Active
- 2014-10-15 SI SI201430841T patent/SI3057969T1/sl unknown
- 2014-10-16 SM SM20180448T patent/SMT201800448T1/it unknown
- 2014-10-16 UY UY0001035787A patent/UY35787A/es active IP Right Grant
- 2014-10-16 TW TW103135888A patent/TWI683814B/zh active
-
2015
- 2015-10-20 US US14/887,614 patent/US9994575B2/en active Active
-
2016
- 2016-03-17 IL IL24467716A patent/IL244677B/en active IP Right Grant
- 2016-03-22 ZA ZA2016/01970A patent/ZA201601970B/en unknown
- 2016-04-05 PH PH12016500611A patent/PH12016500611A1/en unknown
-
2017
- 2017-04-04 US US15/479,145 patent/US9944651B2/en active Active
-
2018
- 2018-05-07 US US15/973,378 patent/US10807985B2/en active Active
- 2018-08-21 CY CY20181100868T patent/CY1121182T1/el unknown
- 2018-11-30 JP JP2018224481A patent/JP6782756B2/ja active Active
-
2020
- 2020-10-14 US US17/070,556 patent/US20210284645A1/en not_active Abandoned
-
2021
- 2021-03-03 NL NL301094C patent/NL301094I2/nl unknown
- 2021-03-03 HU HUS2100006C patent/HUS2100006I1/hu unknown
- 2021-03-11 CY CY2021007C patent/CY2021007I2/el unknown
- 2021-03-16 LT LTPA2021003C patent/LTC3057969I2/lt unknown
- 2021-03-18 NO NO2021012C patent/NO2021012I1/no unknown
-
2022
- 2022-11-09 US US17/983,747 patent/US11827642B2/en active Active
-
2023
- 2023-10-23 US US18/382,727 patent/US20240317757A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
| DK3074027T3 (da) | Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf | |
| LT2961410T (lt) | Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| HUE049637T2 (hu) | Toalettben lehúzható katéterek | |
| LT2984166T (lt) | Kompozicijos, skirtos mpsi gydymui | |
| IL241191B (en) | Local compositions and kits that include them for the treatment of local disorders | |
| EP2889350A4 (en) | ADHESIVE COMPOSITION | |
| DK2943549T3 (da) | Synergistisk h2s-scavenger-sammensætning | |
| DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
| DK3027750T3 (da) | Biokatalytisk sammensætning | |
| EP3012292A4 (en) | PROCESSING AGENTS AND COMPOSITION | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| DK2956010T4 (da) | Fedtsammensætning | |
| ES2651188T8 (es) | Composición líquida fotopolimerizable | |
| DK3498000T3 (da) | MRS-konfiguration i to niveauer | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| PL2988750T5 (pl) | Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii | |
| PL3032022T3 (pl) | Sposób montażu urządzenia ciągnącego i zestaw montażowy | |
| GB2533234B (en) | Ocular composition and kits thereof | |
| LT3052625T (lt) | Notch 1 specifinės sirnr molekulės | |
| BR112015018892A2 (pt) | kit ortopédico veterinario. | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| DK3071282T3 (da) | Kateterpunktursæt |